A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors

This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of BGB-B3227, a humanized immunoglobulin G1 (IgG1) antibody. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-B3227 as a monotherapy or in combination with tislelizumab with or without chemotherapy in participants with selected advanced or metastatic solid tumors. The study will also identify recommended dose(s) for expansion (RDFE[s]) of BGB-B3227 administered alone and in combination with tislelizumab.

Study Overview

• Status: Terminated
• Conditions: Metastatic Cancer; Advanced Solid Tumor; Metastatic Solid Tumor; Advanced Cancer
• Intervention / Treatment: Drug: Tislelizumab; Drug: BGB-B3227; Drug: Chemotherapy

• Study Type: Interventional
• Enrollment (Actual): 35
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China, 100142
      • Beijing Cancer Hospital
    • Beijing, Beijing Municipality, China, 100021
      • Cancer Hospital Chinese Academy of Medical Sciences
  • Shanghai Municipality
    • Shanghai, Shanghai Municipality, China, 200032
      • Affiliated Zhongshan Hospital of Fudan University
• Italy
  • Milan, Italy, 20133
    • Fondazione IRCCS Istituto Nazionale dei Tumori
  • Milan, Italy, 20141
    • Istituto Europeo di Oncologia
  • Roma, Italy, 00168
    • Fondazione Policlinico Universitario Agostino Gemelli
  • Rozzano, Italy, 20089
    • Istituto Clinico Humanitas
• United States
  • California
    • Los Angeles, California, United States, 90089-1019
      • Usc Norris Comprehensive Cancer Center (Nccc)
  • Missouri
    • St Louis, Missouri, United States, 63110-1010
      • Washington University in St Louis
  • New Jersey
    • Hackensack, New Jersey, United States, 07601-1915
      • Hackensack University Medical Center
  • Texas
    • Austin, Texas, United States, 78758
      • NEXT Oncology
    • Houston, Texas, United States, 77030-3907
      • MD Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Histologically or cytologically confirmed locally advanced or metastatic solid tumors with a high prevalence of mucin-1 (MUC1) expression
• At least 1 measurable lesion per RECIST v1.1
• Stable Eastern Cooperative Oncology Group Performance Status of ≤ 1
• Adequate organ function
• Willing to use a highly effective method of birth control

Exclusion Criteria:

• History of prior ≥ Grade 3 Cytokine Release Syndrome (CRS)
• History of severe Infusion-Related Reactions (IRRs), allergic reactions, or hypersensitivity to any ingredients or components of the study treatments
• Infection requiring systemic (oral or intravenous) therapy ≤ 14 days before the first dose of study drug(s), or participants with symptomatic COVID-19 infection
• Active leptomeningeal disease or uncontrolled, untreated brain metastasis
• Active autoimmune disease or history of autoimmune disease(s) that may relapse

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phase 1a Part A: Dose Escalation (BGB-B3227 Monotherapy); Sequential cohorts of increasing dose levels of BGB-B3227 will be evaluated as monotherapy.	Drug: BGB-B3227; Administered intravenously.
Experimental: Phase 1a Part B: Dose Escalation (BGB-B3227 + tislelizumab); Sequential cohorts of increasing dose levels of BGB-B3227 will be evaluated in combination with tislelizumab.	Drug: Tislelizumab; Administered intravenously.; Other Names: BGB-A317; Drug: BGB-B3227; Administered intravenously.
Experimental: Phase 1b: Dose Expansion; Sequential cohorts of increasing dose levels of BGB-B3227 will be evaluated in combination with tislelizumab and chemotherapy.	Drug: Tislelizumab; Administered intravenously.; Other Names: BGB-A317; Drug: BGB-B3227; Administered intravenously.; Drug: Chemotherapy; Administered in accordance with relevant local guidelines and/or prescribing information.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 1b: Objective Response Rate (ORR)	ORR is defined as the percentage of participants with confirmed best overall response of complete response (CR) or partial response (PR), as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.	From first dose of study drug(s) until progressive disease or new anticancer treatment; approximately 12 months
Phase 1b: Recommended Phase 2 Dose (RP2D) of BGB-B3227	RP2D established from Phase 1a for BGB-B3227 for administration in combination with tislelizumab and chemotherapy in selected tumor types.	Approximately 12 months
Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)	Number of participants with AEs and SAEs, including findings from physical examinations, laboratory assessments, and that meet protocol-defined dose-limiting toxicity (DLT) criteria or protocol-defined Adverse Event of Special Interest (AESI) criteria.	From first dose of the study drug(s) to 30 days after the last dose or 90 days after last dose of tislelizumab, approximately 9 months
Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD)	MTD is defined as the highest dose evaluated for which estimated toxicity rate is the closest to the target toxicity rate. MAD is defined as the highest dose administered if MTD is not reached.	Approximately 9 months
Phase 1a: Recommended Dose(s) for Expansion (RDFE[s]) of BGB-B3227	RDFE of BGB-B3227 alone or in combination with tislelizumab will be determined based upon the MTD or MAD.	Approximately 9 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 1a: ORR	ORR is defined as the percentage of participants with confirmed best overall response of CR or PR, as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.	From first dose of study drug(s) until progressive disease or new anticancer treatment; approximately 6 months
Phase 1b: Progression-Free Survival (PFS)	PFS is defined as the time from the first dose of study treatment to the date of first documentation of disease progression or death, whichever occurs first, as assessed by the investigator per RECIST Version 1.1.	From first dose of study drug(s) until progressive disease or new anticancer treatment; approximately 12 months
Phase 1a and 1b: Disease Control Rate (DCR)	DCR is defined as the percentage of participants who achieve confirmed CR, PR, or stable disease, as assessed by the investigator per RECIST Version 1.1.	From first dose of study treatment drug(s) until confirmed response or stable disease; approximately 6 months for Phase 1a and 12 months for Phase 1b
Phase 1a and 1b: Duration of Response (DoR)	DoR is defined as the time from the first confirmed objective response to disease progression documented after treatment initiation or death, whichever occurs first, as assessed by the investigator per RECIST Version 1.1.	From confirmed response to disease progression or death; approximately 6 months for Phase 1a and 12 months for Phase 1b
Phase 1a and 1b: Number of Participants with Antidrug Antibodies (ADAs) against BGB-B3227		From first dose of BGB-B3227 up to 30 days after last dose of BGB-B3227; approximately 6 months for Phase 1a and 12 months for Phase 1b
Phase 1b: Number of Participants with AEs and SAEs	Number of participants with AEs and SAEs, including findings from physical examinations, laboratory assessments, and that meet protocol-defined dose-limiting toxicity (DLT) criteria or protocol-defined Adverse Event of Special Interest (AESI) criteria.	From first dose of the study drug(s) to 30 days after the last dose, or 90 days after last dose of tislelizumab; approximately 12 months
Phase 1a and 1b: Serum Concentrations of BGB-B3227		From first dose of BGB-B3227 up to 30 days after last dose of BGB-B3227; approximately 6 months for Ph1a and 12 months for Ph1b
Phase 1a: Area under the Curve (AUC) of BGB-B3227		Approximately 4 months
Phase 1a: Maximum observed plasma concentration (Cmax) of BGB-B3227		Approximately 4 months
Phase 1a: Time to reach maximum observed plasma concentration (Tmax) of BGB-B3227		Approximately 4 months
Phase 1a: Trough concentration (Ctrough) of BGB-B3227		Approximately 4 months
Phase 1a: Accumulation ratio of BGB-B3227		Approximately 4 months
Phase 1a: Terminal half-life (t1/2) of BGB-B3227		Approximately 4 months

Collaborators and Investigators

• Sponsor: BeiGene
• Investigators: Study Director: Study Director, BeiGene

Study record dates

Study Major Dates

• Study Start (Actual): September 11, 2024
• Primary Completion (Actual): January 9, 2026
• Study Completion (Actual): January 9, 2026

Study Registration Dates

• First Submitted: August 2, 2024
• First Submitted That Met QC Criteria: August 2, 2024
• First Posted (Actual): August 6, 2024

Study Record Updates

• Last Update Posted (Actual): March 16, 2026
• Last Update Submitted That Met QC Criteria: March 13, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: advanced solid tumor; metastatic solid tumor; tislelizumab; BGB-A317; BGB-B3227
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Neoplastic Processes; Pathological Conditions, Signs and Symptoms; Neoplasm Metastasis; Therapeutics; Drug Therapy; tislelizumab
• Other Study ID Numbers: BGB-B3227-101; 2024-514216-27-00 (Ctis); CTR20244018 (Registry Identifier: ChinaDrugTrials)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

• IPD Sharing Time Frame: See plan description
• IPD Sharing Access Criteria: See plan description
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No